enzalutamide + abiraterone + prednisone
Phase 3UNKNOWN 0 views this week 0 watching💤 Quiet
Interest: 36/100
36
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Adenocarcinoma of the Prostate
Conditions
Adenocarcinoma of the Prostate, Hormone-resistant Prostate Cancer, Recurrent Prostate Cancer, Stage IV Prostate Cancer
Trial Timeline
Jan 22, 2014 → Aug 31, 2024
NCT ID
NCT01949337About enzalutamide + abiraterone + prednisone
enzalutamide + abiraterone + prednisone is a phase 3 stage product being developed by Astellas Pharma for Adenocarcinoma of the Prostate. The current trial status is unknown. This product is registered under clinical trial identifier NCT01949337. Target conditions include Adenocarcinoma of the Prostate, Hormone-resistant Prostate Cancer, Recurrent Prostate Cancer.
What happened to similar drugs?
1 of 20 similar drugs in Adenocarcinoma of the Prostate were approved
Approved (1) Terminated (1) Active (18)
Hype Score Breakdown
Clinical
17
Activity
4
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01949337 | Phase 3 | UNKNOWN |
Competing Products
20 competing products in Adenocarcinoma of the Prostate